Listed

Lakewood-Amedex Biotherapeutics Inc.

LABTNasdaqCIK 2079272HealthcareFiscal year ends Dec 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.8m, Q2 FY2026
Net income−$3.8m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Cost of revenue$knot reportednot reported507Cost of revenue, Q1 FY2026, three months to 2026-03-31$507.3k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figurenot reported
Research and development$k170Research and development, period not labelled, three months to 2025-03-31$169.7k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure147Research and development, period not labelled, three months to 2025-06-30$146.9k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure182Research and development, Q1 FY2026, three months to 2026-03-31$182.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure503Research and development, Q2 FY2026, three months to 2026-06-30$503.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Operating income$k(543)Operating income, period not labelled, three months to 2025-03-31−$542.6k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure(637)Operating income, period not labelled, three months to 2025-06-30−$637.4k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(887)Operating income, Q1 FY2026, three months to 2026-03-31−$886.8k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure(3,790)Operating income, Q2 FY2026, three months to 2026-06-30−$3.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Interest expense$k1.3Interest expense, period not labelled, three months to 2025-03-31$1.3k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure23.9Interest expense, period not labelled, three months to 2025-06-30$23.9k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure38.2Interest expense, Q1 FY2026, three months to 2026-03-31$38.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure10.6Interest expense, Q2 FY2026, three months to 2026-06-30$10.6k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Net income$k(540)Net income, period not labelled, three months to 2025-03-31−$539.6k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(656)Net income, period not labelled, three months to 2025-06-30−$655.9k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(923)Net income, Q1 FY2026, three months to 2026-03-31−$923.3k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(3,772)Net income, Q2 FY2026, three months to 2026-06-30−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Diluted EPS$ per share(0.15)Diluted EPS, period not labelled, three months to 2025-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure(1.66)Diluted EPS, period not labelled, three months to 2025-06-30−$1.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(0.20)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure(2.75)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Basic EPS$ per share(0.15)Basic EPS, period not labelled, three months to 2025-03-31−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure(1.66)Basic EPS, period not labelled, three months to 2025-06-30−$1.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(0.20)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure(2.75)Basic EPS, Q2 FY2026, three months to 2026-06-30−$2.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure

Balance sheet

Cash and equivalents$2.6m, Q2 FY2026
Shareholders' equity$4.3m, Q2 FY2026
Line itemUnitperiod not labelled2024-12-31period not labelled2025-03-31period not labelled2025-06-30period not labelled2025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$knot reportednot reportednot reported236Cash and equivalents, period not labelled, at 2025-12-31$236.4k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure11.7Cash and equivalents, Q1 FY2026, at 2026-03-31$11.7k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure2,585Cash and equivalents, Q2 FY2026, at 2026-06-30$2.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Current assets$knot reportednot reportednot reported305Current assets, period not labelled, at 2025-12-31$305.4k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure50.6Current assets, Q1 FY2026, at 2026-03-31$50.6k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure4,845Current assets, Q2 FY2026, at 2026-06-30$4.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Total assets$knot reportednot reportednot reported482Total assets, period not labelled, at 2025-12-31$481.6k. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure196Total assets, Q1 FY2026, at 2026-03-31$196.3k. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure4,960Total assets, Q2 FY2026, at 2026-06-30$5.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Current liabilities$knot reportednot reportednot reported2,405Current liabilities, period not labelled, at 2025-12-31$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure3,028Current liabilities, Q1 FY2026, at 2026-03-31$3.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure629Current liabilities, Q2 FY2026, at 2026-06-30$628.9k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Total liabilities$knot reportednot reportednot reported2,446Total liabilities, period not labelled, at 2025-12-31$2.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure3,038Total liabilities, Q1 FY2026, at 2026-03-31$3.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure629Total liabilities, Q2 FY2026, at 2026-06-30$628.9k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure
Shareholders' equity$k410Shareholders' equity, period not labelled, at 2024-12-31$409.6k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(76.2)Shareholders' equity, period not labelled, at 2025-03-31−$76.2k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(683)Shareholders' equity, period not labelled, at 2025-06-30−$683.3k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(1,965)Shareholders' equity, period not labelled, at 2025-12-31−$2.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure(2,842)Shareholders' equity, Q1 FY2026, at 2026-03-31−$2.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure4,331Shareholders' equity, Q2 FY2026, at 2026-06-30$4.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure

Cash flow

Operating cash flow−$2.1m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(404)Operating cash flow, period not labelled, three months to 2025-03-31−$404.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure(509)Operating cash flow, period not labelled, three months to 2025-06-30−$508.6k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001213900-26-089380. Derived: 6-month figure less the 3-month figure.Report this figure(350)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$349.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure(2,104)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001213900-26-089380. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)1.42m, Q2 FY2026
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)k shares6,943Diluted shares (weighted), period not labelled, three months to 2025-03-316,943,494 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure694Diluted shares (weighted), period not labelled, three months to 2025-06-30694,450 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure6,995Diluted shares (weighted), Q1 FY2026, three months to 2026-03-316,995,469 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-22, accession 0001213900-26-060640.Report this figure1,420Diluted shares (weighted), Q2 FY2026, three months to 2026-06-301,419,767 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure

Shares outstanding: 2.37mShares outstanding, period not labelled, at 2026-08-032,369,688 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-089380.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.